1-3 of 3
Elodie Gadolet, CRA
Close
Sort by
Journal Articles

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Helene Labussiere, MD, PhD, Madeleine Etienne, CRA, Marie-Pierre Fort, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Kaddour Chabane, Eric Lippert, MD, Mohamad Sobh, Pharm.M., Stephanie Dulucq, MD, Stephane Morisset, Stat., Mauricette Michallet, Francois-Xavier Mahon, MD, PhD, Gabriel Etienne, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 1684.
https://doi.org/10.1182/blood.V118.21.1684.1684
Published: 2011
Journal Articles

Shorter Time to Achieve a Major Molecular Response (MMR) Is Predictive of a Faster Complete Molecular Response in CML: A Study of Characteristics and Outcomes of a Cohort of CML Patients in MMR

Mauricette Michallet, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Madeleine Etienne, CRA, Elodie Gadolet, CRA, Helene Labussiere, MD, Sandrine Hayette, PhD, Franck E. Nicolini, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 1691.
https://doi.org/10.1182/blood.V118.21.1691.1691
Published: 2011
Journal Articles

The Achievement of Early Major Molecular Response In Early Chronic Phase Chronic Myeloid Leukemia on Imatinib 400 Mg/Day Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival.

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Lila Gilis, MD, Madeleine Etienne, CRA, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Helene Labussiere, MD, Luc Gerland, MD, Damien Waz, MStud, Mohamad Sobh, Pharm., M, Stephane Morisset, Stat., Mauricette Michallet
Journal: Blood
Blood (2010) 116 (21): 3407.
https://doi.org/10.1182/blood.V116.21.3407.3407
Published: 2010